top of page

SEYLTX

News and Events

Jul 16, 2024

Seyltx Announces Positive Pre-Clinical Dose-Ranging Data with Its Selective Oral Inhibitor of GluN2B Illustrating Near-Complete Suppression of Refractory Chronic Cough within the Therapeutic Index

CAMBRIDGE, MA, JULY 16, 2024 (GLOBE NEWSWIRE) – Seyltx, Inc. (“Seyltx” or the “Company”), a clinical-stage biopharmaceutical company...

Jul 11, 2024

Seyltx Announces Results of Electronic Health Record Analysis to Determine the Prevalence of Refractory Chronic Cough

CAMBRIDGE, MA - JULY 09, 2024 -Data will be presented at the London International Cough Symposium on July 18, 2024 - 54,958,289 adult...

Press Releases

Scientific Publications

Dose-Ranging of The Selective GluN2B Allosteric Inhibitor Ifenprodil Illustrates Near-Complete Cough Suppression Within The Therapeutic Index

Presented at the London International Cough Symposium, July 18-29, London, UK

A Composite Diagnostic Signature for Accurate Identification of Refractory Chronic Cough (RCC) Patients from Electronic Health Records (EHR)

Seyltx Announces Positive Pre-Clinical Dose-Ranging Data with Its Selective Oral Inhibitor of GluN2B Illustrating Near-Complete Suppression of Refractory Chronic Cough within the Therapeutic Index

bottom of page